Literature DB >> 33487659

Subcutaneous Infusion of Pamidronate in a Hospice Patient with Hypercalcemia: A Case Report.

Chris Vandevelde1, Jordan Ho2.   

Abstract

Entities:  

Year:  2021        PMID： 33487659      PMCID： PMC7801332     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  8 in total

1.  The use of subcutaneous pamidronate.

Authors:  Alison R Duncan
Journal:  J Pain Symptom Manage       Date:  2003-07       Impact factor: 3.612

Review 2.  Clinical practice. Hypercalcemia associated with cancer.

Authors:  Andrew F Stewart
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

3.  Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity.

Authors:  P Walker; S Watanabe; P Lawlor; J Hanson; J Pereira; E Bruera
Journal:  Ann Oncol       Date:  1997-09       Impact factor: 32.976

Review 4.  Cancer-Related Hypercalcemia.

Authors:  Whitney Goldner
Journal:  J Oncol Pract       Date:  2016-05       Impact factor: 3.840

Review 5.  Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.

Authors:  C S Kovacs; S M MacDonald; C L Chik; E Bruera
Journal:  J Pain Symptom Manage       Date:  1995-04       Impact factor: 3.612

6.  Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration.

Authors:  Célia Roemer-Bécuwe; Antonio Vigano; Fabrizio Romano; Catherine Neumann; John Hanson; Hue K Quan; Paul Walker
Journal:  J Pain Symptom Manage       Date:  2003-09       Impact factor: 3.612

Review 7.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

8.  Prevalence of hypercalcemia among cancer patients in the United States.

Authors:  Victor M Gastanaga; Lee S Schwartzberg; Rajul K Jain; Melissa Pirolli; David Quach; Jane M Quigley; George Mu; W Scott Stryker; Alexander Liede
Journal:  Cancer Med       Date:  2016-06-05       Impact factor: 4.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.